FR2364656A1 - Medicament anti-tumeur a base de compose du type lysolecithine - Google Patents

Medicament anti-tumeur a base de compose du type lysolecithine

Info

Publication number
FR2364656A1
FR2364656A1 FR7713522A FR7713522A FR2364656A1 FR 2364656 A1 FR2364656 A1 FR 2364656A1 FR 7713522 A FR7713522 A FR 7713522A FR 7713522 A FR7713522 A FR 7713522A FR 2364656 A1 FR2364656 A1 FR 2364656A1
Authority
FR
France
Prior art keywords
lysolecithin
type compound
product based
medicinal product
tumor medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7713522A
Other languages
English (en)
Other versions
FR2364656B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of FR2364656A1 publication Critical patent/FR2364656A1/fr
Application granted granted Critical
Publication of FR2364656B1 publication Critical patent/FR2364656B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet un médicament anti-tumeur constitué par, ou contenant un composé de formule générale I :
FR7713522A 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine Granted FR2364656A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Publications (2)

Publication Number Publication Date
FR2364656A1 true FR2364656A1 (fr) 1978-04-14
FR2364656B1 FR2364656B1 (fr) 1980-03-07

Family

ID=5977045

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7713522A Granted FR2364656A1 (fr) 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine

Country Status (15)

Country Link
JP (1) JPS52134027A (fr)
AU (1) AU517586B2 (fr)
BE (1) BE854270A (fr)
CA (1) CA1094455A (fr)
DE (1) DE2619686C2 (fr)
FR (1) FR2364656A1 (fr)
GB (1) GB1583661A (fr)
IE (1) IE44927B1 (fr)
IL (1) IL51988A (fr)
IT (1) IT1071329B (fr)
LU (1) LU77248A1 (fr)
NL (1) NL189672C (fr)
NZ (1) NZ183981A (fr)
SE (1) SE7705071L (fr)
ZA (1) ZA772649B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2450608A1 (fr) * 1979-03-05 1980-10-03 Toyama Chemical Co Ltd Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396311A (en) * 1977-01-29 1978-08-23 Toyama Chem Co Ltd Anti-cander drugs containing lysolecithins
JPS5528955A (en) * 1978-08-24 1980-02-29 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative, its salt, their preparation, and carcinostatic agent containing the same.
US4408052A (en) * 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4551532A (en) * 1980-05-08 1985-11-05 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
JPS5772914A (en) 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
EP0061872B1 (fr) * 1981-03-30 1985-08-07 Takeda Chemical Industries, Ltd. Dérivés de l'éthylèneglycol, leur production et utilisation
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3131524A1 (de) * 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
EP0103877B1 (fr) * 1982-09-21 1987-01-07 Fujisawa Pharmaceutical Co., Ltd. Dérivés phosphatés, leur procédé de préparation et médicaments les contenant
US4710579A (en) * 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4761404A (en) * 1985-07-01 1988-08-02 Merck & Co., Inc. Phospholipid analogs useful as PAF synthesis inhibitors
DE3662197D1 (en) * 1985-07-15 1989-04-06 Takeda Chemical Industries Ltd 2-alkanoyloxypropane derivatives, their production and use
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE3935580C2 (de) * 1989-10-25 1998-05-28 Medmark Pharma Gmbh Verwendung eines pharmazeutischen Wirkstoffes zur Behandlung von HIV-Infektionen
WO1992019627A2 (fr) * 1991-04-25 1992-11-12 The University Of British Columbia Phosphonates et phosphinates utilises comme agents anticancereux, anti-inflammatoires, antiallergiques et anti-myocardites
ES2034885B1 (es) * 1991-07-10 1994-03-01 Menarini Lab Procedimiento para la preparacion de cetoalquilglicerofosfolipidos.
CA2199179A1 (fr) * 1994-10-14 1996-04-25 Eric Mayhew Liposomes comportant des lipides ethers et leur utilisation therapeutique
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5965159A (en) * 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6135426A (en) * 1998-01-07 2000-10-24 Briggs And Stratton Corporation Priming system for internal combustion engines
RU2009121838A (ru) 2006-11-10 2010-12-20 Альфаптозе ГмбХ (DE) Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина
JP5773569B2 (ja) * 2006-11-10 2015-09-02 アルファプトーゼ ゲーエムベーハーＡｌｐｈａｐｔｏｓｅ Ｇｎｂｈ 受容体リガンド模倣体を検出する方法
CN101616676B (zh) * 2006-12-20 2015-09-09 汉堡-艾本德大学医学中心 三取代的甘油化合物用于治疗恶性血液病的应用
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
WO2013156630A1 (fr) 2012-04-20 2013-10-24 Alphaptose Gmbh Enantiomère s d'un composé glycérol tri-substitué

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2033361C3 (de) * 1970-07-06 1980-02-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(13)-phosphorsäurecholinester und Verfahren zu deren Herstellung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2450608A1 (fr) * 1979-03-05 1980-10-03 Toyama Chemical Co Ltd Agent carcinostatique et immunostimulant contenant un lysophospholipide et un phospholipide et procede pour le preparer

Also Published As

Publication number Publication date
BE854270A (fr) 1977-11-04
LU77248A1 (fr) 1977-12-13
SE7705071L (sv) 1977-11-05
NL189672B (nl) 1993-01-18
IL51988A0 (en) 1977-07-31
NL189672C (nl) 1993-06-16
JPS6146455B2 (fr) 1986-10-14
DE2619686A1 (de) 1977-11-24
FR2364656B1 (fr) 1980-03-07
IT1071329B (it) 1985-04-02
JPS52134027A (en) 1977-11-09
CA1094455A (fr) 1981-01-27
AU2481977A (en) 1978-11-09
DE2619686C2 (de) 1986-08-07
IE44927L (en) 1977-11-04
GB1583661A (en) 1981-01-28
IE44927B1 (en) 1982-05-19
IL51988A (en) 1981-05-20
ZA772649B (en) 1978-04-26
NL7704723A (nl) 1977-11-08
NZ183981A (en) 1980-04-28
AU517586B2 (en) 1981-08-13

Similar Documents

Publication Publication Date Title
FR2364656A1 (fr) Medicament anti-tumeur a base de compose du type lysolecithine
FR2429593A1 (fr) Medicaments contenant des derives d'imidazole
FR2364210A1 (fr) Ethers phenyliques heterocycliques et produits herbicides qui en contiennent
FR2400512A1 (fr) Nouveaux nitro-imidazoles, leur preparation et leur application en tant que medicaments
FR2372810A1 (fr) Nouvelles aminoalcoylimidazolidinones, procedes pour leur preparation et leur utilisation en tant que medicaments
FR2394534A1 (fr) Nouveaux 1-aryloxy-2-hydroxy-3-alcoyleneaminopropanes, procedes pour leur preparation et medicaments les renfermant
FR2361329A1 (fr) Nouvelles fluoroacylresorcines substituees et medicaments, cosmetiques et pesticides les renfermant
FR2359810A1 (fr) Bis-tetrahalogenophtalates d'alkylene ou de cycloalkylene-ammonium, leur preparation et leur application a la preparation d'imides correspondants
FR2377392A1 (fr) Nouveaux medicaments derives de la meta-trifluoromethyl-phenylpiperazine
FR2370737A1 (fr) Imidazole-carboxamides substitues a l'azote, leur obtention et composition pharmaceutique en contenant
FR2386523A1 (fr) Derives du prostane et medicaments qui en contiennent
FR2358384A1 (fr) Peptides psychopharmacologiquement actifs et derives de ces peptides
FR2355021A1 (fr) Nouveaux derives d'imidazothiazine et leur application en tant que medicaments
FR2395993A1 (fr) Derives du prostane a triple liaison en 18 et medicaments qui en contiennent
FR2358890A1 (fr) Nouvelles aryl trifluoroethylamines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
FR2370745A1 (fr) Nouveaux derives de la morphanthridine, leur preparation et leur application comme medicaments
FR2375252A1 (fr) Nouveaux glucosides antitumoraux
FR2355830A1 (fr) Nouveaux derives de 6-7-benzomorphane, leur obtention et composition pharmaceutique les contenant
FR2429020A1 (fr) 1-b-d-arabinofuranosylcytosine-5'-oleyl phosphate et ses sels, et medicaments contenant ces substances
BE862872A (fr) Medicament a base d'un compose heterocyclique bicyclique condense
FR2405954A1 (fr) Nouveaux polyols contenant du phosphore, leur obtention et leur application
FR2356643A1 (fr) 5-0-acyl-imidazole-4-carboxamides, leur obtention et composition pharmaceutique en contenant
FR2367761A1 (fr) Derives piperidylideniques de benzo-xanthenes,
FR2354317A1 (fr) Benzyl-cyanoacetals, leur preparation et leur utilisation pour des syntheses chimiques
FR2392002A1 (fr) 1a-hydroxy-24-dehydrovitamine d3 et medicament contenant cette substance